Marshall Wace
XFOR icon

Marshall Wace’s X4 Pharmaceuticals XFOR Stock Holding History

Marshall Wace’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-336,834
Closed -$1.39M – 3815
2026
Q1 		$1.39M Buy
336,834
+256,378
+319% +$960K ﹤0.01% 1974
2025
Q4 		$322K Buy
+80,456
New +$292K ﹤0.01% 2425
2023
Q4 		– Sell
-430
Closed -$14.1K – 2659
2023
Q3 		$14.1K Sell
430
-23,048
-98% -$1.01M ﹤0.01% 2120
2023
Q2 		$1.37M Buy
+23,478
New +$1.21M ﹤0.01% 1596
2022
Q2 		– Sell
-437
Closed -$23K – 3911
2022
Q1 		$23K Sell
437
-1,579
-78% -$90.6K ﹤0.01% 3261
2021
Q4 		$139K Buy
2,016
+1,175
+140% +$149K ﹤0.01% 3286
2021
Q3 		$133K Buy
841
+384
+84% +$63.2K ﹤0.01% 2855
2021
Q2 		$89K Buy
+457
New +$115K ﹤0.01% 2543

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace's XFOR Position: Q2 2026 in Review

Marshall Wace sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 336,834 shares — an estimated $1.39M sold.

Marshall Wace first reported a position in XFOR in Q2 2021 and held it in 8 quarters. The position peaked at $1.39M in Q1 2026. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Marshall Wace reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 336,834 X4 Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
  • Marshall Wace first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Marshall Wace's X4 Pharmaceuticals position peaked at $1.39M in Q1 2026.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.